Literature DB >> 26619158

L-DOPA-Coated Manganese Oxide Nanoparticles as Dual MRI Contrast Agents and Drug-Delivery Vehicles.

Birgitte Hjelmeland McDonagh1, Gurvinder Singh2, Sjoerd Hak3, Sulalit Bandyopadhyay1, Ingrid Lovise Augestad4, Davide Peddis5, Ioanna Sandvig4,6, Axel Sandvig4,7, Wilhelm Robert Glomm1,8.   

Abstract

Manganese oxide nanoparticles (MONPs) are capable of time-dependent magnetic resonance imaging contrast switching as well as releasing a surface-bound drug. MONPs give T2/T2* contrast, but dissolve and release T1-active Mn(2+) and L-3,4-dihydroxyphenylalanine. Complementary images are acquired with a single contrast agent, and applications toward Parkinson's disease are suggested.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  MRI; contrast agents; drug delivery; l-DOPA; manganese; manganese oxide

Mesh：

Substances：

Year:  2015        PMID： 26619158     DOI： 10.1002/smll.201502545

Source DB:  PubMed          Journal:  Small        ISSN： 1613-6810            Impact factor:   13.281


  11 in total

Review 1.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

2.  Core-shell NaGdF4@CaCO3 nanoparticles for enhanced magnetic resonance/ultrasonic dual-modal imaging via tumor acidic micro-enviroment triggering.

Authors:  Zuwu Wei; Xiao Lin; Ming Wu; Bixing Zhao; Ruhui Lin; Da Zhang; Yun Zhang; Gang Liu; Xiaolong Liu; Jingfeng Liu
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

3.  Phosphatidylserine-Targeted Nanotheranostics for Brain Tumor Imaging and Therapeutic Potential.

Authors:  Lulu Wang; Amyn A Habib; Akiva Mintz; King C Li; Dawen Zhao
Journal:  Mol Imaging       Date:  2017-01-01       Impact factor: 4.488

4.  Artificially controlled degradable nanoparticles for contrast switch MRI and programmed cancer therapy.

Authors:  Tianyang Yun; Yuxin Liu; Shaoqiong Yi; Qi Jia; Yang Liu; Jing Zhou
Journal:  Int J Nanomedicine       Date:  2018-10-24

5.  Coating Dependent In Vitro Biocompatibility of New Fe-Si Nanoparticles.

Authors:  Mihaela Balas; Florian Dumitrache; Madalina Andreea Badea; Claudiu Fleaca; Anca Badoi; Eugenia Tanasa; Anca Dinischiotu
Journal:  Nanomaterials (Basel)       Date:  2018-07-05       Impact factor: 5.076

6.  Tumor-Activatable Clinical Nanoprobe for Cancer Imaging.

Authors:  Derek Reichel; Manisha Tripathi; Pramod Butte; Rola Saouaf; J Manuel Perez
Journal:  Nanotheranostics       Date:  2019-05-04

Review 7.  The Renal Clearable Magnetic Resonance Imaging Contrast Agents: State of the Art and Recent Advances.

Authors:  Xiaodong Li; Yanhong Sun; Lina Ma; Guifeng Liu; Zhenxin Wang
Journal:  Molecules       Date:  2020-11-01       Impact factor: 4.411

Review 8.  Nano-Neurotheranostics: Impact of Nanoparticles on Neural Dysfunctions and Strategies to Reduce Toxicity for Improved Efficacy.

Authors:  Chiluka Vinod; Srikanta Jena
Journal:  Front Pharmacol       Date:  2021-03-26       Impact factor: 5.810

9.  Surface design and preparation of multi-functional magnetic nanoparticles for cancer cell targeting, therapy, and imaging.

Authors:  Jing Qu; Zhijie Tian; Qiuyue Wang; Si Peng; Jian-Bin Luo; Qing-Han Zhou; Juan Lin
Journal:  RSC Adv       Date:  2018-10-16       Impact factor: 3.361

10.  Tuneable manganese oxide nanoparticle based theranostic agents for potential diagnosis and drug delivery.

Authors:  Kingsley Poon; Zufu Lu; Yves De Deene; Yogambha Ramaswamy; Hala Zreiqat; Gurvinder Singh
Journal:  Nanoscale Adv       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.